Neurocrine to acquire Soleno in $2.9B deal to expand into metabolic diseases
Synopsis
Neurocrine enters metabolic disease space with $2.9B Soleno acquisition.
The Neurocrine Soleno acquisition metabolic diseases deal marks a major strategic shift as Neurocrine Biosciences moves beyond neuroscience into new therapeutic areas.
Key highlights
- Neurocrine to acquire Soleno for $2.9 billion in cash
- Deal adds rare disease drug Vykat XR to portfolio
- Marks expansion into metabolic disorders
Deal strengthens rare disease portfolio
Neurocrine Biosciences will acquire Soleno Therapeutics for $2.9 billion in cash.
The offer values Soleno at $53 per share. This represents a premium of about 34% to its previous closing price. The transaction is expected to close within 90 days.
Flagship drug drives acquisition value
The deal gives Neurocrine access to Vykat XR.
This is the first approved treatment in the US for hyperphagia linked to Prader-Willi syndrome. The condition causes extreme hunger and can lead to severe obesity and related complications.
Vykat XR generated about $190 million in sales in 2025 after its approval in March.
Growth potential seen as major
Executives and analysts see strong upside for the drug. Also, CEO Kyle Gano described Vykat XR as a potential blockbuster.
Some estimates suggest the drug could cross $1 billion in annual sales by 2029.
However, the company is currently focused on the US market and has no immediate plans for Europe.
Strategic shift beyond neuroscience
The acquisition marks a broader expansion strategy.
Neurocrine currently sells drugs such as Ingrezza and Crenessity. These generated combined revenue of $2.81 billion in 2025.
With this deal, the company adds a new growth pillar in metabolic diseases.
Funding and financial impact
Neurocrine said it will fund the acquisition using cash reserves. It also plans to raise a modest amount of debt to support the deal.
The company expects the acquisition to boost long-term earnings and strengthen its market position.
Australia angle: Healthcare and pharma implications
For Australia, the deal highlights key trends in the global pharmaceutical sector:
Growing focus on rare and metabolic diseases could influence drug development priorities.
Australian healthcare providers may see increased access to innovative treatments over time.
Global biotech consolidation could shape partnerships and investment flows in the sector.
What next?
The deal is expected to close within three months.
Investors will watch how quickly Neurocrine integrates Soleno and expands Vykat XR’s reach. The future growth will depend on adoption rates and potential expansion into new markets.
FAQs
Q1: What is the Neurocrine-Soleno deal?
Neurocrine is acquiring Soleno Therapeutics for $2.9 billion in cash.
Q2: What drug is included in the deal?
Vykat XR, used to treat hyperphagia in Prader-Willi syndrome.
Q3: Why is this acquisition important?
It expands Neurocrine into metabolic diseases beyond neuroscience.
Q4: What is the growth potential?
The drug could generate over $1 billion in annual sales in the coming years.
Follow Inspirepreneur Magazine for daily global business news.
I write about markets, money, and the macro forces that move them. Passionate about turning complex economic trends into sharp, easy-to-understand stories. Off the clock, it’s hip hop, rock, reggae -- and a mix of cricket and basketball.
